Table 5

Quantitative image analysis of histological changes produced by R115777 treatment of human tumor xenografts

Tumor (origin)TreatmentApoptosisaProliferationaAngiogenesisb
ISELBrdUc/Ki-67dFactor VIIIVEGF
Lo VoVehicle1.99 ± 0.7030.3 ± 1.673.26 ± 0.4111.6 ± 1.26
(colon)R115777
25 mg/kg3.10 ± 0.9825.2 ± 7.681.76 ± 0.39e8.88 ± 2.52
50 mg/kg2.90 ± 0.5322.1 ± 8.10a1.29 ± 0.29a7.21 ± 1.54
CAPAN-2 (pancreatic)Vehicle5.54 ± 3.0027.2 ± 2.372.16 ± 0.3441.3 ± 3.90
R115777
50 mg/kg9.56 ± 4.2621.9 ± 1.54e2.94 ± 0.7641.2 ± 1.80
100 mg/kg10.6 ± 3.00e13.0 ± 0.93e2.43 ± 0.8137.2 ± 2.34
C32 (melanoma)Vehicle4.38 ± 2.9030.4 ± 16.16.8 ± 0.4238.1 ± 3.07
R115777
25 mg/kg21.7 ± 19.7e35.1 ± 14.46.09 ± 0.5039.1 ± 2.88
50 mg/kg44.2 ± 23.6a37.7 ± 6.534.98 ± 0.3036.9 ± 3.12
100 mg/kg42.0 ± 26.8e35.2 ± 7.165.13 ± 0.6443.5 ± 4.05
  • a Data expressed as the percentage of the area per slide with staining signal for VEGF or Factor III. Values are means ± SD.

  • b Data expressed as the percentage of cells staining positive.

  • c Analysis of Lo Vo and CAPAN-2 tumors only.

  • d Analysis of C32 melanoma.

  • e Statistically significant (P < 0.05) form vehicle controls by Wilcoxon Mann-Whitney U Test.